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In recent years, with the change of china’s population structure,and gradually 
increase the pressure of people’s lives, ”sub-health” phenomenon is increasingly common, 
traditional Chinese medicine keeping in good health, the concept of “to prevent diseases” 
is deeply rooted in the hearts of the people gradually, as the development of 《traditional 
Chinese medicine “shisanwu” planning》lauch and implement step by step and 《The Laws 
of  Traditional Chinese Medicine》 issue and implemented, also reflected the national 
guidance of support and encourage of traditional Chinese medicine industry. Yunnan 
Paiyao and Tong Ren Tang are brands with a long history of traditional Chinese medicine 
enterprises in China, and the domestic two landmark Chinese medicine enterprises, the 
development of the two companies witnessed the development of Chinese medicines, the 
two companies’future development of  strategic path selection affects the development of 
Chinese medicine industry. This article through to the two companies’ strategic path 
selection, development direction and financial performance to conduct a comprehensive 
analysis and comparison, through the strategic choice for the two companies and its 
impact on the financial performance of comparative analysis, it is concluded that the two 
domestic heavyweight enterprise beneficial inspiration and suggestions of Chinese 
medicine to make a beneficial exploration. 
In this paper, the instruction clarify the research background and significance of this 
article, and clarify the research content and framework, it is the outline of contract section. 
Industry analysis in this paper, the second chapter mainly analyzes our country macro 
economic development and its influence on the development of the pharmaceutical 
industry, and analyze the industry development situation of Chinese medicine ,is the basis 
of this article. 
The third chapter of this paper mainly discusses the development of Yunnan Paiyao 
and Tong Ren Tang and their strategic analysis respectively, to research the two companies’ 
strengths,weaknesses,opportunities and challenges facing, made a simple analysis about 
the two companies’ strategic choices. 
The fourth of this paper mainly make a comparative analysis of Yunnan Paiyao and 
Tong Ren Tang’s accounting policy and financial statements, and make three dimensional 















companies’  nearly five years of financial performance were comparatively analyzed. 
Chapter 5 of this article is mainly to Yunnan Paiyao and Tong Ren Tang comparing 
relevant financial ratio analysis, analysis of the two companies’ profitability,efficient use 
of assets and liabilities management ability, cash ability, growth ability, management risk 
and financial risk and value creation ability differences, and how the two companies’ 
strategic development path choice lead to these differences. 
The sixth chapter of this article is conclusion and suggestion part, through the above 
analysis, we try to give suggestion for Yunnan Paiyao and Tong Ren Tang about future 
development path selection and management, and also hope to draw beneficial 
enlightenment to the domestic industry of  Chinese medicine development. 
 























第一章  导论 ................................................................................................... 1 
第一节 研究背景与意义 .............................................................................................. 1 
第二节 研究内容与框架 .............................................................................................. 2 
第二章  中医药行业分析 ............................................................................... 3 
第一节 宏观经济发展状况分析及其对医药行业的影响 .......................................... 3 
第二节 中医药行业发展状况 ...................................................................................... 4 
一、中医药行业分析 ............................................................................................. 4 
二、中医药行业发展现状 ..................................................................................... 4 
第三章  云南白药和同仁堂的发展历程和战略分析 ................................... 8 
第一节 第三节云南白药与同仁堂基本情况比较 ...................................................... 8 
第二节 云南白药的发展历程和战略分析 .................................................................. 9 
一、云南白药简介及发展历程 ............................................................................. 9 
二、云南白药战略分析 ........................................................................................ 11 
第三节 同仁堂的发展历程和战略分析 .................................................................... 14 
一、同仁堂简介及发展历程 ............................................................................... 14 
二、同仁堂战略分析 ........................................................................................... 15 
第四节 云南白药和同仁堂的发展战略对比 ............................................................ 18 
一、产品定位的差异 ........................................................................................... 19 
二、发展路径选择的差异 ................................................................................... 19 
三、市场竞争战略的差异 ................................................................................... 19 
四、财务战略的差异 ........................................................................................... 19 
第五节 云南白药和同仁堂面临的机遇和挑战 ........................................................ 20 
一、中医药行业相关政策带来的机遇 ............................................................... 20 
二、大健康领域潜在市场巨大带来的机遇 ....................................................... 20 
三、互联网的飞速发展带来的机遇 ................................................................... 20 















五、成本上升带来的挑战 ................................................................................... 21 
第四章  云南白药和同仁堂的财务报表三维分析 ..................................... 22 
第一节 资产负债表三维分析 .................................................................................... 22 
一、资产负债总量分析 ....................................................................................... 22 
二、资产负债表结构分析 ................................................................................... 23 
三、资产负债表趋势分析 ................................................................................... 24 
第二节 利润表三维分析 ............................................................................................ 25 
一、利润表总量分析 ........................................................................................... 25 
二、利润表构成分析 ........................................................................................... 26 
三、利润表趋势分析 ........................................................................................... 27 
第三节 现金流量表三维分析 .................................................................................... 28 
一、现金流量表总量分析 ................................................................................... 28 
二、现金流量表构成分析 ................................................................................... 29 
三、现金流量表趋势分析 ................................................................................... 30 
第四节 财务报表三维分析总结 ................................................................................ 30 
第五章  云南白药与同仁堂财务比率分析 ................................................. 32 
第一节 盈利能力分析 ................................................................................................ 32 
一、销售盈利能力分析 ....................................................................................... 32 
二、总资产收益率比较 ....................................................................................... 34 
三、资本利润率比较 ........................................................................................... 34 
四、三项费用对比 ............................................................................................... 35 
五、盈利能力分析结论 ....................................................................................... 35 
第二节 资产使用效率分析 ........................................................................................ 36 
一、总资产使用效率分析 ................................................................................... 36 
二、流动资产使用效率分析 ............................................................................... 37 
三、应收账款周转效率分析 ............................................................................... 37 
四、存货周转效率分析 ....................................................................................... 38 
五、现金转化周期对比 ....................................................................................... 39 















第三节 负债管理指标分析 ........................................................................................ 40 
一、资产流动性分析 ........................................................................................... 41 
二、付息还本能力分析 ....................................................................................... 42 
三、负债管理分析结论 ....................................................................................... 43 
第四节 现金创造能力指标分析 ................................................................................ 43 
一、从销售、资产、资本、权益的现金创造能力看 ....................................... 44 
二、从获现率及利润的现金含量看 ................................................................... 45 
三、现金创造能力分析结论 ............................................................................... 46 
第五节 增长能力指标分析 ........................................................................................ 46 
一、自我可持续增长率影响因素分解分析 ....................................................... 47 
二、增长能力分析结论 ....................................................................................... 47 
第六节 经营风险和财务风险指标分析 .................................................................... 48 
一、经营风险分析 ............................................................................................... 49 
二、财务风险分析 ............................................................................................... 49 
三、风险分析结论 ............................................................................................... 49 
第七节 创值能力（EVA）指标分析 ........................................................................ 50 
一、从 ROIC 与 WACC 的关系来看 .................................................................. 51 
二、从税后 ROIC 与销售创值能力看 ............................................................... 52 
三、从资产与资本创值能力看 ........................................................................... 53 
四、创值能力的比较分析结论 ........................................................................... 53 
第八节 同行业主要财务数据比较分析 .................................................................... 55 
第六章  战略选择与财务业绩的关系分析 ................................................. 56 
第一节 战略选择差异对于收入构成变化趋势的影响 ............................................ 56 
一、云南白药收入构成变动趋势分析 ............................................................... 56 
二、同仁堂收入构成变动趋势分析 ................................................................... 56 
三、云南白药与同仁堂收入构成对比分析 ....................................................... 57 
第二节 战略选择差异对财务指标及财务比率的影响分析 .................................... 57 
第三节 战略选择差异对增长能力和创值能力的影响分析 .................................... 58 















第一节 研究结论 ........................................................................................................ 59 
第二节 研究建议 ........................................................................................................ 60 
一、给国内医药企业的启示 ............................................................................... 60 
二、给云南白药的建议 ....................................................................................... 61 
三、给同仁堂的建议 ........................................................................................... 61 
第三节 研究的不足之处 ............................................................................................ 62 
附录：云南白药与同仁堂财务报表 ............................................................. 63 
参考文献.......................................................................................................... 70 


















Chapter 1 Introduction ·········································· 1 
Section1 Research Background and Significance ····························· 1 
Section2 Research Contents and Frame····································· 2 
Chapter 2 Chinese Medicine Industry Analysis ······················ 3 
Section1 Analysis of Macroeconomic Development and  its impact on the 
Pharmaceutical Industry ················································· 3 
Section2 Development of Traditional Chinese Medicine Industry ·············· 4 
Part1 Analysis of Traditional Chinese Medicine Industry ··················· 4 
Part2 Development status of traditional Chinese medicine industry ··········· 4 
Chapter 3 The development and strategic analysis of Yunnan Baiyao and 
Tongrentang ··················································· 8 
Section1 Basic Comparison of Yunnan Baiyao and Tongrentang ········ 8 
Section2The development and strategic analysis of Yunnan Baiyao  ············ 9 
Part1 Brief introduction and development of Yunnan Baiyao ················ 9 
Part2 Strategic analysis of Yunnan Baiyao ······························· 11 
Section3 The development and strategic analysis of Tongrentang··············14 
Part1 Brief introduction and development of Tongrentang ·················· 14 
Part2Strategic analysis of Tongrentang ································· 15 
Section4 Comparison of development strategy of Yunnan Baiyao and 
Tongrentang ···························································18 
Part 1 Product positioning differences ································· 19 
Part 2 Differences in development path choice ··························· 19 
Part3 Differences in market competitive strategies ························ 19 
Part4 Differences in financial strategy ································· 19 
Section 5 Opportunities and challenges faced by Yunnan Baiyao and 
Tongrentang ···························································20 
Part1 Opportunities broughted by Chinese medicine industry related policies ·· 20 
Part2 Opportunities brought by Great potential in the field of health market ···· 20 















Part4 Market competition intensifies, challenges to the traditional Chinese 
medicine industry ················································· 21 
Part5 Challenges brought by Rising cost ······························· 21 
Chapter 4 Three dimensional analysis of financial statements of Yunnan 
Baiyao and Tongrentang········································ 22 
Section1 Three dimensional analysis of balance sheet ························22 
Part1 Total balance sheet analysis ····································· 22 
Part2 Analysis of balance sheet structure ······························· 23 
Part3 Balance sheet trend analysis ···································· 24 
Section2 Three dimensional analysis of income statement ····················25 
Part1 Total profit statement analysis ··································· 25 
Part2 Income statement analysis ······································ 26 
Part3 Income statement trend analysis ································· 27 
Section3 Three dimensional analysis of cash flow statement ··················28 
Part1 Total cash flow statement ······································· 28 
Part2 Analysis of cash flow statement ·································· 29 
Part3 Cash flow statement trend analysis ······························· 30 
Section4 Three dimensional analysis of financial statements ··················30 
Chapter 5 Analysis of financial ratios of Yunnan Baiyao and 
Tongrentang ·················································· 32 
Section1 Profitability analysis ············································32 
Part1 Sales profitability analysis ······································ 32 
Part2 Return on total assets comparion ································· 34 
Part3 Capital profit ratio comparison ·································· 34 
Part4 Three cost comparison ········································· 35 
Part5 Profitability analysis conclusions ································ 35 
Section2 Asset use efficiency analysis ······································36 
Part1 Analysis of total assets using efficiency ··························· 36 
Part2 Analysis of current assets use efficiency ··························· 37 
Part3 Accounts receivable turnover efficiency analysis ···················· 37 
Part4 Inventory turnover efficiency analysis····························· 38 
Part5 Cash conversion cycle comparison ······························· 39 















Section3 Analysis of debt management index ·······························40 
Part1 Asset liquidity analysis ········································ 41 
Part2 Analysis of interest paying ability ································ 42 
Part3 Analysis of debt management ··································· 43 
Section4 Index analysis of cash creation ability ·····························43 
Part1 From the perspective of sales, assets, capital and equity ··············· 44 
Part2 From the cash ratio of profit and profit ···························· 45 
Part3 Analysis of cash creation ability ································· 46 
Section5 Analysis of growth ability index ··································46 
Part1 Analysis of factors affecting sustainable growth rate ················· 47 
Part2 Growth capacity analysis conclusion ······························ 47 
Section6 Analysis of operational risk and financial risk index ·················48 
Part1 Operating risk analysis········································· 49 
Part2 Financial risk analysis ········································· 49 
Part3 Risk analysis conclusion ······································· 49 
Section7 The ability to create value (EVA) index analysis ····················50 
Part1 From the perspective of the relationship between ROIC and WACC ····· 51 
Part2 From the perspective of value creation ability and sales tax ROIC ······· 52 
Part3 From the asset and capital value creation ability ····················· 53 
Part4 The conclusion of comparative analysis of the value creation ability  ···· 53 
Section8 Comparative analysis of major financial data in the same industry ····55 
Chapter6 Analysis of the relationship between strategic choice and 
financial performance ·········································· 56 
Section1The influence of different strategic choices on the trend of income 
structure ······························································56 
Part1 Analysis on the changing trend of income components of Yunnan Baiyao · 56 
Part2 Analysis on the changing trend of income components of Tongrentang ··· 56 
Part3 Comparative analysis on the income structure of Yunnan Baiyao and 
Tongrentang ······················································ 57 
Section2Analysis of the influence of different strategic choices on financial 
indicators and financial ratios ············································57 
Section3Analysis of the impact of war strategy differences on growth ability and 















Chapter7Conclusion and suggestion ······························ 59 
Section1 Research Conclusion ············································59 
Section2 Research Suggestion ············································60 
Section3 Deficiency of research ···········································62 
Appendix:Financial statements of Yunnan Baiyao and Tongrentang ··· 63 
Reference ····················································· 70 














第一章  导论 
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去的五十年里，健康产业的增长速度超过了世界的 GDP 增速，世界经济总量的 8%-10%
要归功于健康产业。相对于发达国家而言，我国的健康产业占 GDP 的比重仍处于较
低水平，我国健康产业有着巨大发展空间。2013 年 10 月国务院印发《关于促进健康
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